Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the addition of Tislelizumab after definitive local
therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with
local therapy as well as treat micro metastatic disease and improve one year progression-free
survival rates for participants and optimize local control.